Sudden loss of the GVL effect following use of the TNF inhibitor infliximab in a chronic myelogenous leukemia patient with chronic GVHD.
Veeraputhiran
M
M
Mangan
K
K
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease; D020544:Graft vs Leukemia Effect / Q000187:drug effects*; D006801:Humans; D000069285:Infliximab; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab